202 GSK Annual Report 2017 Notes to the financial statements continued 34.
Movements in equity Retained earnings and other reserves amounted to 4,430 million at 31 December 2017 2016 3,172 million: 2015 943 million of which 334 million 2016 329 million: 2015 283 million relates to joint ventures and associated undertakings.
The cumulative translation exchange in equity is as follows: Net translation exchange included in: NonTotal Retained Fair value controlling translation earnings reserve interests exchange m m m m At 1 January 2015 137 4 117 250 Exchange movements on overseas net assets 624 6 8 610 At 31 December 2015 761 10 109 860 Exchange movements on overseas net assets 633 13 603 1,249 At 31 December 2016 128 23 494 389 Exchange movements on overseas net assets 462 149 313 Reclassification of exchange on liquidation or disposal of overseas subsidiaries 109 109 At 31 December 2017 443 23 345 811 The analysis of other comprehensive income by equity category is as follows: NonRetained Other controlling earnings reserves interests Total 2017 m m m m Items that may be subsequently reclassified to income statement: Exchange movements on overseas net assets and net investment hedges 462 462 Reclassification of exchange on liquidation or disposal of overseas subsidiaries 109 109 Fair value movements on available-for-sale investments 14 14 Reclassification of fair value movements on available-for-sale investments 42 42 Deferred tax on fair value movements on available-for-sale investments 47 47 Deferred tax reversed on reclassification of available for sale investments 18 18 Fair value movements on cash flow hedges 10 10 Items that will not be reclassified to income statement: Exchange movements on overseas net assets of non-controlling interests 149 149 Remeasurement gains on defined benefit plans 549 549 Tax on remeasurement gains in defined benefit plans 221 221 Other comprehensive income expense for the year 899 37 149 713 NonRetained Other controlling earnings reserves interests Total 2016 m m m m Items that may be subsequently reclassified to income statement: Exchange movements on overseas net assets and net investment hedges 633 13 646 Fair value movements on available-for-sale investments 251 251 Reclassification of fair value movements on available-for-sale investments 245 245 Deferred tax reversed on reclassification of available-for-sale investments 51 51 Reclassification of cash flow hedges to income statement 1 1 Fair value movements on cash flow hedges 2 2 Deferred tax on fair value movements on cash flow hedges 2 2 Items that will not be reclassified to income statement: Exchange movements on overseas net assets of non-controlling interests 603 603 Remeasurement losses on defined benefit plans 475 475 Tax on remeasurement losses in defined benefit plans 126 126 Other comprehensive income for the year 284 75 603 962 203 GSK Annual Report 2017 Strategic report Governance and remuneration Financial statements Investor information 34.
Movements in equity continued NonRetained Other controlling earnings reserves interests Total 2015 m m m m Items that may be subsequently reclassified to income statement: Exchange movements on overseas net assets and net investment hedges 624 6 618 Fair value movements on available-for-sale investments 416 416 Deferred tax on fair value movements on available-for-sale investments 91 91 Reclassification of fair value movements on available-for-sale investments 346 346 Deferred tax reversed on reclassification of available-for-sale investments 36 36 Reclassification of cash flow hedges to income statement 2 2 Fair value movements on cash flow hedges 2 2 Share of other comprehensive expense of associates and joint ventures 77 77 Items that will not be reclassified to income statement: Exchange movements on overseas net assets of non-controlling interests 8 8 Remeasurement gains on defined benefit plans 261 261 Tax on remeasurement gains in defined benefit plans 80 80 Other comprehensive expense income for the year 520 25 8 487 The analysis of other reserves is as follows: ESOP Trust Fair value Cash flow Other shares reserve hedge reserve reserves Total m m m m m At 1 January 2015 151 274 13 2,129 2,239 Transferred to income and expense in the year on disposals 356 2 354 Transferred to income and expense in the year on impairments 10 10 Net fair value movement in the year 367 2 369 Ordinary shares acquired by ESOP Trusts 99 99 Write-down of shares held by ESOP Trusts 175 175 At 31 December 2015 75 295 9 2,129 2,340 Transferred to income and expense in the year on disposals 16 268 284 Transferred to income and expense in the year on impairments 23 23 Net fair value movement in the year 330 6 336 Ordinary shares acquired by ESOP Trusts 576 576 Write-down of shares held by ESOP Trusts 381 381 At 31 December 2016 286 380 3 2,129 2,220 Transferred to income and expense in the year on disposals 22 42 20 Transferred to income and expense in the year on impairments Net fair value movement in the year 9 8 17 Ordinary shares acquired by ESOP Trusts 656 656 Write-down of shares held by ESOP Trusts 520 520 At 31 December 2017 400 329 11 2,129 2,047 Other reserves include various non-distributable merger and pre-merger reserves amounting to 1,849 million at 31 December 2017 2016 1,849 million: 2015 1,849 million.
Other reserves also include the capital redemption reserve created as a result of the share buy-back programme amounting to 280 million at 31 December 2017 2016 280 million: 2015 280 million.
